Katabi Maha
- SEC CIK
- 0001720685
No open-market purchases or sales filed in the past year.
Current role at each company
- VERA Vera Therapeutics, Inc.Directoras of May 16, 2025
- JBIO Jade Biosciences, Inc.Director, 10% Owneras of Jun 7, 2024
- RYZB RayzeBio, Inc.Directoras of Feb 27, 2024
- CINC CinCor Pharma, Inc.10% Owneras of Feb 27, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Katabi Maha as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
VERA Vera Therapeutics, Inc.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2024 (view filing) | Mar 21-25 | 4 days | Katabi MahaDirector | SSaleClass A Common Stock | −834.5K | $40.86 | −$34.1M | −23.0%2.79M after | 6 lots |
| Feb 1, 2024 (view filing) | Jan 30 | 2 days | Katabi MahaDirector | PPurchaseClass A Common Stock | +161.3K | $31.00 | +$5.00M | +4.7%3.63M after | |
| Feb 8, 2023 (view filing)6:29 PM ET | Feb 6 | 2 days | Katabi Maha and 4 othersDirector, 10% Owner | PPurchaseClass A Common Stock | +285.7K | $7.00 | +$2.00M | +9.0%3.47M after | |
| Feb 14, 2022 (view filing)6:17 PM ET | Feb 10 | 4 days | Katabi Maha and 3 othersDirector, 10% Owner | PPurchaseClass A Common Stock | +266.7K | $15.00 | +$4.00M | +9.1%3.18M after |
RYZB RayzeBio, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2023 (view filing) | Sep 19 | 2 days | Katabi MahaDirector | PPurchase | +472.2K | $18.00 | +$8.50M | +64.0%1.21M after | 2 lots |
CINC CinCor Pharma, Inc.
10% Owner3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2023 (view filing)9:15 PM ET | Nov 28, 2022 | 91 daysLate | Healy James and 4 othersDirector, 10% Owner | SSale | −6.00K | $14.32 | −$85.9K | −100.0%0 after | |
| Aug 15, 2022 (view filing)3:46 PM ET | Aug 11 | 4 days | Sofinnova Management X, L.P. and 2 others10% Owner | PPurchase | +500.0K | $30.00 | +$15.0M | +9.0%6.07M after | |
| Jan 13, 2022 (view filing)4:38 PM ET | Jan 11 | 2 days | Sofinnova Management X, L.P. and 2 others10% Owner | PPurchase | +325.0K | $16.00 | +$5.20M | +6.2%5.57M after | Duplicate filing |
JBIO Jade Biosciences, Inc.
Director, 10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2021 (view filing) | Jul 2 | 4 days | Katabi MahaDirector, 10% Owner | PPurchase | +357.1K | $14.00 | +$5.00M | +10.5%3.76M after |